Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

This study has been completed.
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT01432600
First received: September 9, 2011
Last updated: April 18, 2017
Last verified: February 2017
  Purpose
The main purpose of this study is to see whether pomalidomide can help people with myeloma. Researchers also want to find out if pomalidomide is safe and tolerable.

Condition Intervention Phase
Myeloma
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Cyclophosphamide
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma

Resource links provided by NLM:


Further study details as provided by H. Lee Moffitt Cancer Center and Research Institute:

Primary Outcome Measures:
  • Phase I - Maximum Tolerated Dose (MTD) [ Time Frame: 28 Days ]
    The maximum tolerated dose of oral weekly cyclophosphamide in milligrams (mg), in combination with pomalidomide and dexamethasone. Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows: Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg. The period for assessment of Dose Limiting Toxicity (DLT) is the first cycle (28 days). The following toxicities will be considered dose limiting if encountered only in the phase I portion of the study: Febrile neutropenia; Grade 3 or 4 non-hematologic toxicity related to treatment with pomalidomide or cyclophosphamide; Participants must have received optimal symptomatic treatment for Grade 3 or 4 nausea, vomiting, or diarrhea to be considered a DLT; Grade 4 transaminitis; Grade 3 transaminitis must be present for ≥ 7 days to be considered a DLT; Grade 4 thrombocytopenia for 7 or more days; Grade 4 neutropenia for 7 or more days.

  • Phase II - Overall Response Rate (ORR) [ Time Frame: 36 Months ]
    Overall response, Minimal Remission (MR) or better per treatment arm, using the uniform response criteria by the International Myeloma Working Group (IMWG) of pomalidomide in combination with high dose dexamethasone with or without cyclophosphamide in participants with relapsed and refractory myeloma. In addition, Minimal response was incorporated in those response criteria as this is a valid endpoint in patients with relapsed or refractory myeloma. MR: 25-49% reduction in serum paraprotein and a 50-89% reduction in urine light chain excretion; A 25-49% reduction in the size of soft tissue plasmacytoma must be demonstrated is applicable.


Secondary Outcome Measures:
  • Phase II - Median Progression Free Survival (PFS) [ Time Frame: 36 Months ]
    Progression free survival per treatment arm. Progressive Disease (PD) requires one of the following, increase of greater than or equal to 25% from baseline in: Serum M-component; Urine M-component; The difference between involved and uninvolved sFLC levels; The size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia.

  • Phase II - Median Overall Survival (OS) [ Time Frame: 36 Months ]
    Overall survival per treatment arm. Overall survival is defined as the time from start of treatment to death of any cause.

  • Phase II - Occurrence of Possibly Related Adverse Events (AEs) [ Time Frame: Up to 48 Months ]
    Phase II: Participants with Grade 3 or 4 adverse events at least possibly related to the study treatment in 5% of participants in the Phase 2 portion, by AE category, assessed by the National Cancer Institute Common Terminology Criteria (NCI CTC) version 4.0.


Enrollment: 80
Study Start Date: November 2011
Study Completion Date: August 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A: Dose Escalation of Cyclophosphamide

Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide:

Pomalidomide 4 mg by mouth (PO) days 1-21 of a 28 days cycle.

Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.

Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows:

Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg.

Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications).

Drug: Pomalidomide
Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
Other Name: CC-4047, POMALYST®
Drug: Dexamethasone
Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
Other Name: Decadron®
Drug: Cyclophosphamide
The dose escalation uses a standard "3x3" design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
Other Name: Cytoxan
Active Comparator: B: Pomalidomide and Dexamethasone

Randomized Phase II - Pomalidomide high dose dexamethasone:

Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.

Dexamethasone 40* mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.

Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications).

Drug: Pomalidomide
Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
Other Name: CC-4047, POMALYST®
Drug: Dexamethasone
Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
Other Name: Decadron®
Active Comparator: C: Pomalidomide/Dexamethasone/Cyclophosphamide

Randomized Phase II - Pomalidomide high dose dexamethasone and oral cyclophosphamide:

Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.

Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.

Cyclophosphamide 400 mg PO days 1, 8, 15.

Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications).

Drug: Pomalidomide
Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
Other Name: CC-4047, POMALYST®
Drug: Dexamethasone
Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
Other Name: Decadron®
Drug: Cyclophosphamide
The dose escalation uses a standard "3x3" design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
Other Name: Cytoxan
D: Crossover
Crossover from Arm B to Arm D. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician, in which case oral weekly Cyclophosphamide (400 mg orally on days 1, 8, and 15) was added to their tolerated dose of pomalidomide and dexamethasone.
Drug: Pomalidomide
Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
Other Name: CC-4047, POMALYST®
Drug: Dexamethasone
Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
Other Name: Decadron®
Drug: Cyclophosphamide
The dose escalation uses a standard "3x3" design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
Other Name: Cytoxan

Detailed Description:

There are two parts to this study:

  • Phase 1: To determine a safe dose of the medication cyclophosphamide in combination with pomalidomide and dexamethasone.
  • Phase 2: To see the difference in effectiveness of pomalidomide in combination with high dose dexamethasone with or without cyclophosphamide for the treatment of participants who have myeloma, which has relapsed to or become refractory (not responding) to prior treatment.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must have relapsed or refractory multiple myeloma. Refractory disease is defined as patients who experience disease progression on active therapy or within 60 days after the discontinuation of therapy. Relapsed disease is defined as achievement of at least a partial response followed by disease progression after 60 days of discontinuing active therapy.
  • Must have measurable disease as assessed by one of the following criteria: Serum monoclonal protein ≥ 0.5 g/dL by protein electrophoresis; >200 mg of monoclonal protein in the urine on 24 hour electrophoresis; Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
  • Must have received at least 2 prior therapies to include prior immunomodulatory drug (lenalidomide) and the patient must be refractory to lenalidomide (defined as progressive disease during active therapy or within 60 days of discontinuation of therapy). All previous cancer chemotherapy (bisphosphonates are not included), including surgery, must have been discontinued ≥2 weeks prior to first dose of study drug. Prior radiotherapy must have been completed > 2 weeks prior to the start of study drug unless the radiation field would not impact marrow reserve in the opinion of the investigator.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%
  • Must have acceptable organ function: total bilirubin less than 1.5 mg/dL; aspartic transaminase (AST)/alanine transaminase (ALT) ≤2.5 X institutional upper limit of normal (ULN); serum creatinine < 3mg/dL
  • Must have adequate hematologic function as evidenced by the following:
  • For the Phase I study: Absolute neutrophil count (ANC) ≥ 1000 per mm³; Platelet count ≥ 50,000 per mm³.
  • For the Phase II portion, patients with greater than 50% bone marrow plasmacytosis will be allowed to enter the trial if the platelet count is greater than 30,000 per mm³ and regardless of baseline absolute neutrophil count if it is felt to be related to active myeloma and if in the opinion of the investigator, growth factor support can result in improvement in the neutrophil count to greater than 1000 per mm³ (growth factor can be used during screening).
  • Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy.
  • Ability to understand and the willingness to sign a written informed consent document
  • Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid (ASA) may use warfarin or low molecular weight heparin).
  • All study participants must be registered into the mandatory POMALYST REMS™ program, and be willing and able to comply with the requirements of the POMALYST REMS™ program.

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 2 weeks (see Inclusion Criteria above) or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier (except for neuropathy).
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form
  • Any condition, including the presence of laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. Use of any other experimental drug or therapy within 28 days of baseline.
  • Known hypersensitivity to thalidomide or lenalidomide
  • The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, pomalidomide or similar drugs
  • Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
  • May not be receiving any other investigational agents
  • Pregnant or breast feeding females (Lactating females must agree not to breast feed while taking pomalidomide).
  • Patients with prior pomalidomide therapy (greater than 1 cycle) are excluded.
  • Another active malignancy requiring treatment within the next 12 months, with the exception of basal cell skin cancer, in situ cervical cancer, in situ breast cancer and asymptomatic prostate cancer
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (except simple urinary tract or upper respiratory tract infection), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Inability to comply with the protocol requirements or participation in any other clinical study
  • Corticosteroid therapies of >20 mg/day prednisone, >4 mg/day dexamethasone, >80 mg/day hydrocortisone, or equivalent
  • Allogeneic stem cell/bone marrow transplant within 12 months of first dose of study drug or active graft versus host disease
  • Patients with existing peripheral neuropathy grade >2
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01432600

Locations
United States, California
University of California San Francisco
San Francisco, California, United States, 94143
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
United States, New York
Mount Sinai School of Medicine, The Tisch Cancer Institute
New York, New York, United States, 10029-6574
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Celgene
Investigators
Principal Investigator: Rachid Baz, M.D. H. Lee Moffitt Cancer and Research Institute
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier: NCT01432600     History of Changes
Other Study ID Numbers: MCC-16705
PO-MM-PI-0039 ( Other Grant/Funding Number: Celgene )
Study First Received: September 9, 2011
Results First Received: March 6, 2017
Last Updated: April 18, 2017

Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
Multiple Myeloma
Relapsed
Refractory
Corticosteroids

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Dexamethasone
Dexamethasone 21-phosphate
Pomalidomide
Cyclophosphamide
Thalidomide
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on May 25, 2017